2019 Annual Meeting Presentations

Sharon Nachman, MD

PROMISE Findings: What's New? What Have We Learned?

Mary Glenn Fowler, MD, MPH

NIAID: State of the Institute and Priorities for HIV/AIDS Research

Anthony Fauci, MD

Central Nervous System Outcomes in Perinatal HIV: Neurobehavior and Neurobiology

Susan Morgello, MD

Broadly Neutralizing Antibodies to Reduce Vertical HIV Transmission: Safety and PK of VRC01 and VRCO1LS

Coleen Cunningham, MD

Welcome and Overview of Tuberculosis Scientific Agenda

Ultrashort Regimens for TB Prevention in Children and Pregnant Women

Nicole Salazar-Austin Sylvia LaCourse

Optimizing Rifampicin Exposures in Children with Severe and Non-severe TB: the OptiRif Kids trial

Anthony Garcia-Prats

Improving Access to Anti-tuberculosis Drugs for Children: Updates from the World Health Organization

Martina Penazzato

TB Vaccines: State of the Art

Ann Ginsberg

Novel Serum-based Biomarkers for TB Diagnosis in Children

Tony Hu

Welcome and Overview of Treatment Scientific Agenda

Global HIV Treatment Landscape: What’s Next for Women and Children

Martina Penazzato

Current Pipeline of Long-Acting Formulations and Products: Implications for Infants, Children, Adolescents, and Pregnant Women

Charles Flexner

Treatment Studies in the Pipeline

IMPAACT Treatment Scientific Committee Members Discussion: What’s Next on the Treatment Horizon?

Treatment Scientific Committee Members 3

Committee Overview

Pregnancy: A Window of Opportunity to Test and Treat Hepatitis C Virus

Catherine Chappell

New-Onset Seizures in Children with HIV

IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States

Larry Brown

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

Geri Donenberg, Dorothy Dow

RSV Studies IMPAACT 2011, 2012, 2013, 2018, 2021: Randomized Phase I Studies of the Infectivity, Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Betsy McFarland, Coleen Cunningham

Concept Sheet 5020: Low Dose Aspirin for Prevention of Preterm Birth in Women Living With HIV-1

Adriana Weinberg

Welcome: Overview of Prevention Agenda

HIV Drug Resistance at Mother-to-Child Transmission and Emergence during Breastfeeding

Ceejay Boyce

Infant Growth Updates: P1084s and Neurodevelopmental Growth Findings with ARV Exposure

The Outcome of Subsequent Pregnancies in PROMISE 1077BF and 1077FF

Future Plans and Remaining Gaps in Knowledge

Mary Glenn Fowler

Study Update, IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

Phionah Kibalama

PrEP in Pregnancy: Ongoing Projects and Gaps

Grace John-Stewart

Study Update, IMPAACT P1112: Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1 Exposed Infants

Coleen Cunningham

Cost-Effectiveness of Broadly Neutralizing Antibodies for PMTCT in Resource-Limited Settings

Andrea Ciaranello

Study Overview: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted with GLA-SE in Healthy, HIV-exposed Uninfected Infants

Avy Violari

Recent Updates and Guidelines from DAIDS

Anne Coletti

DAIDS Clinical Trials Insurance Requirement, memorandum dated 10 August 2018: Tips for Documentation Needed for CTI as part of Study Activation

Emily Brown

Overview of Relevant Sections of the IMPAACT Network Manual of Procedures

IMPAACT Study Milestones

LDMS End User Validation Lab Assistance Program

Applications of Antiviral Adherence Monitoring with Dried Blood Spots (DBS)

Kristina Brooks

P1090 and P1093 Regulatory Inspection Preparadness

Ellen Townley and Teri Greenfield

Updates: The Revised Common Rule, Informed Consent Process Policy, Age & Identity Verification Policy, Delegation of Duties Policy, and Clinical Quality Mangement Plan Policy

DAIDS OPCRO and OCSO staff

Good Documentation Practices

Skills Building Session: Understanding Informed Consent and Assent

• English
• Português
• Español
• ไทย

Education Session: Undetectable = Untransmittable: Understanding Treatment as Prevention (TasP) and PreExposure Prophylaxis (PrEP)

• English *
• Português 
• Español
• ไทย

U=U and how one CAB, our UCLA CAB, made a difference

Jonathan Lucas, FHI 360

Jayda Arrington – Los Angeles, CA USA

Cure Scientific Committee Update

Treatment Scientific Committee Update

Baylor - Uganda CAB and Community Activities

Prevention Scientific Committee Update

IMPAACT Community and Science HIV Prevention

TB Scientific Committee Update

UZCHS_CRTC IMPAACT Community Advisory Board

Complications Scientific Committee Update

Community Activities for IMPAACT 2016